Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the cost of this innovative drug and its availability have become key concerns for patients and healthcare providers. While tirzepatide has been authorized by regulatory agencies, its costly nature presents a significant barrier to many.